Texas hedge funder Kyle Bass says he's going after drug patents because the pharma industry milks the healthcare system by "evergreening" drug patents. But now, Bass and his Coalition for Affordable Drugs are challenging a patent on Imbruvica, the Johnson & Johnson and Pharmacyclics cancer treatment that was just approved in 2013. Is that evergreening?
Actavis is trying to encourage an appeals court to let it force patients over to a new, patent-protected version of Alzheimer's treatment Namenda. Hundreds of millions in sales rest on the decision. But so far, the judges aren't offering any clues about their answer.
Hedge fund manager Kyle Bass has struck out at drug patents once again. Just weeks after challenging two patents on an Acorda Therapeutics drug, Bass asked the U.S. Patent and Trademark Office to reconsider coverage on two Shire meds, Lialda and Gattex.
In a year when several of his peers won big payoffs for one extraordinary reason or another, Amgen CEO Robert Bradway earned just about as much as he had the previous year, give or take a few hundred thousand. Small comfort--though some comfort, perhaps--to the thousands of employees facing job cuts as Amgen prepares for biosimilar competition to its top-selling meds.
Talk about unintended consequences of a patent ruling. Pfizer's unprecedented effort to fight Lyrica copies in England has doctors and pharmacists squabbling, and the National Health Service stepping in to keep the peace.
Generics makers aren't the only ones filing challenges to pharma patents anymore. Hedge funds are doing it, too, and it's got drugmakers on edge.
The U.S. Patent Office gives, and the U.S. Patent Office takes away. Unfortunately for Johnson & Johnson, it was the latter for Remicade. After a re-examination of Remicade's September 2018 patent, agency officials issued a big fat rejection.
Last month, Texas hedge fund manager Kyle Bass said he had pharma and its "questionable" patents in his sights. Now, he's made his first move--and he's said 14 more targets will follow.
Gilead Sciences might have expected a hepatitis C patent challenge in India. But in Europe? Not so much. But that's exactly what Gilead is getting. After losing its bid for a new Indian patent covering its blockbuster treatment Sovaldi, Gilead is now threatened with a similar action at the European Patent Office in Munich.
India's Cipla argued before the Delhi High Court against the Novartis patent for its Onbrez (indacaterol) COPD drug, saying the patent need not be honored because the Swiss drugmaker was not working it in the country and has licensed it to Lupin instead.